|
Guardant Health Inc (NASDAQ: GH) |
|
GH's Market share relative to its competitors, as of Q1 2025
As of Q1 2025 (Revenue in Millions of $)
Date modified: 2025-06-24T00:08:19+00:00
Select the Relationship:
|
|
Select the Category:
|
|
COMPANY NAME |
REVENUES 12 Months Ending Q1 2025 |
MARKET SHARE 12 Months Q1 2025 |
MARKET SHARE MRQ Q1 2025 |
MARKET SHARE A Quarter Before Q4 2024 |
Guardant Health Inc |
774.00 |
0.99% |
1.07 % |
0.94 % |
Thermo Fisher Scientific Inc |
42,898.00 |
54.85% |
54.67% |
53.33% |
Quest Diagnostics Inc |
10,158.00 |
12.99% |
13.99% |
12.27% |
Lineage Inc |
6,498.95 |
8.31% |
6.82% |
11.86% |
Illumina Inc |
4,337.00 |
5.55% |
5.49% |
5.17% |
Exact Sciences Corporation |
2,821.53 |
3.61% |
3.73% |
3.20% |
Fortrea Holdings Inc |
2,685.60 |
3.43% |
3.44% |
3.26% |
Qiagen N v |
1,919.35 |
2.45% |
2.45% |
0.00% |
Natera Inc |
1,831.00 |
2.34% |
2.65% |
2.23% |
Myriad Genetics Inc |
830.40 |
1.06% |
1.03% |
0.98% |
Neogenomics Inc |
671.88 |
0.86% |
0.88% |
0.81% |
Invitae Corporation |
481.58 |
0.62% |
0.64% |
0.56% |
Veracyte Inc |
422.81 |
0.54% |
0.57% |
0.48% |
Caredx Inc |
346.42 |
0.44% |
0.45% |
0.41% |
Genedx Holdings Corp |
329.46 |
0.42% |
0.46% |
0.45% |
Fulgent Genetics Inc |
292.46 |
0.37% |
0.39% |
0.36% |
Adaptive Biotechnologies Corporation |
189.53 |
0.24% |
0.28% |
0.22% |
Grail Inc |
157.43 |
0.20% |
0.17% |
0.30% |
Personalis Inc |
85.69 |
0.11% |
0.11% |
0.08% |
Biodesix Inc |
74.46 |
0.10% |
0.09% |
0.10% |
Burning Rock Biotech Limited |
70.67 |
0.09% |
0.09% |
0.00% |
Mdxhealth Sa |
70.19 |
0.09% |
0.09% |
0.00% |
Sophia Genetics Sa |
61.91 |
0.08% |
0.08% |
0.00% |
Centogene N v |
54.32 |
0.07% |
0.07% |
0.00% |
Interpace Biosciences Inc |
49.34 |
0.06% |
0.06% |
0.07% |
Bionano Genomics Inc |
28.46 |
0.04% |
0.03% |
0.04% |
Prenetics Global Limited |
21.74 |
0.03% |
0.03% |
0.00% |
Precipio inc |
20.03 |
0.03% |
0.03% |
0.03% |
Dermtech Inc |
13.37 |
0.02% |
0.02% |
0.01% |
Bioaffinity Technologies Inc |
8.81 |
0.01% |
0.01% |
0.01% |
Htg Molecular Diagnostics Inc |
6.21 |
0.01% |
0.01% |
0.01% |
Oncocyte Corporation |
3.70 |
0.00% |
0.01% |
0.01% |
Opgen Inc |
1.96 |
0.00% |
0.00% |
0.00% |
Predictive Oncology Inc |
1.31 |
0.00% |
0.00% |
0.00% |
Volitionrx Limited |
1.31 |
0.00% |
0.00% |
0.00% |
Mainz Biomed N v |
0.90 |
0.00% |
0.00% |
0.00% |
Theralink Technologies Inc |
0.51 |
0.00% |
0.00% |
0.00% |
Sera Prognostics Inc |
0.12 |
0.00% |
0.00% |
0.00% |
Cardio Diagnostics Holdings Inc |
0.02 |
0.00% |
0.00% |
0.00% |
Accustem Sciences Inc |
0.00 |
0.00% |
0.00% |
0.00% |
Aspira Women s Health Inc |
0.00 |
0.00% |
0.02% |
0.00% |
Biocept Inc |
-8.02 |
-0.01% |
0.00% |
0.00% |
SUBTOTAL |
78,212.42 |
100% |
18,956.22 |
100% |
GH's Market share relative to its competitors, as of Q1 2025 within the Medical Laboratories Industry
As of Q1 2025
GH's Market share relative to its competitors, as of Q1 2025 within the Healthcare Sector
As of Q1 2025
Note: Market share is calculated based on total revenue. To get a more accurate picture of Guardant Health Inc's market divisions, geographic dispersion, segments, products, and services, visit Guardant Health Inc's Business Segment. The list includes publicly traded companies only. More information about the sources of this report can be found here.
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com